HDR Brachytherapy for Prostate Cancer

Overseen By Hans Chung, MD

Age: 18+

Sex: Male

Trial Phase: Academic

Sponsor: Sunnybrook Health Sciences Centre

Disqualifiers: Castrate resistance, Prior therapies, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: Acute period (<6 months)

60 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing a treatment where small radioactive seeds are temporarily placed inside the prostate to kill cancer cells. It targets patients whose prostate cancer has come back but hasn't spread. The goal is to see if this focused treatment can reduce side effects compared to treating the whole prostate.

Research Team

Hans Chung, MD

Principal Investigator

Sunnybrook Health Sciences Centre, Odette Cancer Centre

Eligibility Criteria

Men with isolated local recurrence of prostate cancer after initial radiation therapy, who have a solitary recurrence confirmed by MRI and biopsy, PSA levels below 10 ng/mL, prostate volume under 50cc, good performance status (ECOG 0-1), no metastases on CT/MRI or bone scan, manageable urinary symptoms (IPSS < 15), and no prior extensive prostate treatments like TURP or chemotherapy.

Inclusion Criteria

My prostate cancer returned over 30 months after finishing treatment.

American Urological Association Symptom Index Score (IPSS) < 15

My scans show no cancer spread to my abdomen, pelvis, or bones.

Exclusion Criteria

I have undergone treatments like surgery or chemotherapy for prostate cancer.

My prostate cancer is resistant to hormone therapy.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive focal salvage HDR prostate brachytherapy using temporary implantation of radioactive seeds

Acute period (<6 months)

Follow-up

Participants are monitored for acute and late urinary and rectal toxicities, as well as quality of life

5 years

Treatment Details

Interventions

• Focal Salvage HDR Brachytherapy

Trial Overview The trial is testing focal salvage HDR brachytherapy—a targeted internal radiation treatment where radioactive seeds are temporarily implanted in the prostate. This pilot study aims to assess how feasible this approach is and what side effects it might cause when treating only the affected part of the prostate.

Participant Groups

Group I: Focal salvage HDR prostate brachytherapy Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Sunnybrook Health Sciences Centre

Lead Sponsor

Trials

693

Recruited

1,569,000+

Canadian Association of Radiation Oncology

Industry Sponsor

Trials

8

Recruited

500+